Xcout IntelCytosorbents Corporation competitors & alternatives
The 12 closest competitors and alternatives to Cytosorbents Corporation among medical devices companies — ranked by similarity to what Cytosorbents Corporation actually does, not by market-cap band.
Subscribe to see Cytosorbents Corporation’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Cytosorbents Corporation
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
Cytosorbents Corporation at a glance
Cytosorbents Corporation is a medical devices company headquartered in Princeton, United States. It is publicly listed (CTSO) with a market capitalisation of $11.3M. Xcout tracks 18 named people at Cytosorbents Corporation, including Phillip Chan (Chief Executive Officer & Director).
Cytosorbents Corporation leadership
- Phillip ChanChief Executive Officer & Director
- Phillip P. ChanChief Executive Officer
- Vincent J. CapponiPresident & Chief Operating Officer
- Peter J. MarianiChief Financial Officer
- Efthymios N. Deliargyris FACC FESC FSCAIChief Medical Officer
- Robert H. BartlettCo-Chairman of Cardiac Surgery Advisory Board & Consultant
12 more named people on record for Cytosorbents Corporation, with roles, board committees and tenure — see the full roster →
Top 12 Cytosorbents Corporation competitors
Ranked by semantic similarity — how close each company is to Cytosorbents Corporation by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar medical devices company
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
Medical - Devices
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Similar medical devices company
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Similar medical devices company
Glycorex Transplantation AB develops medical devices that utilize proprietary technology to selectively remove specific antibodies from the blood. Its core product, Glycosorb® ABO, enables blood group incompatible organ, stem cell, and heart transplants. Additionally, the company is expanding its applications to include universal blood plasma production and treatments for autoimmune diseases such as rheumatoid arthritis.
Similar medical devices company
Quanta Dialysis Technologies is a medical-device company that develops hemodialysis systems, notably its compact SC+ platform. Its products are intended for use by dialysis providers and healthcare professionals in clinical and home-care settings to treat patients with kidney failure.
Similar medical devices company
Xeltis is a medical technology company that develops bioresorbable cardiovascular implants, such as artificial blood vessels and valves. Utilizing its proprietary Restorex technology, the company's products are designed to be gradually replaced by the patient's own living tissue to treat life-threatening conditions and improve vascular surgery outcomes.
Medical Device
ALung Technologies develops extracorporeal respiratory support devices, including the Hemolung Respiratory Assist System, designed to remove carbon dioxide from blood and support patients with acute respiratory failure. Its products are intended for hospitals and critical-care clinicians treating patients who need respiratory support, including certain patients with severe COPD or who may otherwise require mechanical ventilation.
Similar medical devices company
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Similar medical devices company
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
Similar medical devices company
Coagulation Sciences LLC develops personalized medicine products and analytical instruments, specifically the Multiple Coagulation Test System, for hospitals and blood banks. The company's technology is designed to diagnose coagulation disorders, evaluate multiple treatment therapies, reduce unnecessary blood transfusions, and improve patient safety.
Similar medical devices company
Terumo Corporation is a global enterprise dedicated to the development, manufacturing, and distribution of a wide array of medical products and equipment. Its comprehensive operations are structured across three primary divisions: the Cardiac and Vascular Company, the Medical Care Solutions Company, and the Blood and Cell Technologies Company. The Cardiac and Vascular Company focuses on cardiovascular and neurovascular interventions. Its product portfolio encompasses a variety of devices, including angiographic guidewires, catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, and self-expanding peripheral stents, alongside advanced intravascular ultrasound systems and imaging catheters. This division also develops specialized devices for treating cerebral aneurysms, such as coils, stents, and intrasaccular devices, as well as embolization systems, aspiration catheters, and clot retrievers for ischemic stroke. Furthermore, it supplies critical components for cardiac surgery, including oxygenators and cardio-pulmonary bypass systems, in addition to artificial vascular and stent grafts. The Medical Care Solutions Company addresses a broad spectrum of general medical and patient care needs. Offerings include essential medical supplies like syringes, infusion and syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, and products for pain management and nutritional support, as well as adhesion barriers. This segment also produces consumer health monitoring devices such as blood glucose monitoring systems, disposable needles for pen-injectors, insulin patch pumps, blood pressure monitors, and digital thermometers. Moreover, it provides contract manufacturing services for pharmaceutical companies, specializing in prefilled syringes and devices like prefillable syringes and needles for pharmaceutical packaging. Finally, the Blood and Cell Technologies Company concentrates on products and systems for blood and cell management. Its offerings span blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, and advanced cell expansion systems. Established in 1921, the company was initially known as Sekisen Ken-onki Corporation before adopting its current name, Terumo Corporation, in October 1974. Terumo Corporation maintains its corporate headquarters in Tokyo, Japan.
Similar medical devices company
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Cytosorbents Corporation and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Cytosorbents Corporationand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →